Related Experiment Video
Updated: Aug 26, 2025

A High-Fidelity Porcine Model of Orthotopic Heart Transplantation Following Donation after Circulatory Death
Published on: June 6, 2025
Heart Transplantation With Older Donors: Should There Be an Age Cutoff?
Qiudong Chen1, Jon Kobashigawa2, Dominic Emerson1
1Department of Cardiac Surgery, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.
Insights
Using older donor hearts (≥55 years) for heart transplantation shows similar survival rates but increased nonfatal adverse events in carefully selected recipients. Donor age impacts long-term outcomes.
Area of Science:
- Cardiology
- Transplantation Medicine
- Geriatric Cardiology
Background:
- Heart transplantation is vital but limited by donor organ availability.
- The use of older donor hearts (≥55 years) is debated due to potential outcome disparities.
- Optimizing donor pool utilization is crucial for meeting transplant demand.
Purpose of the Study:
- To compare heart transplant outcomes between recipients of donor hearts aged ≥55 years and those aged <55 years.
- To evaluate the impact of donor age on short- and long-term graft survival and adverse events.
- To assess the viability of utilizing older donor hearts in specific recipient populations.
Main Methods:
- Retrospective review of first-time adult heart transplant recipients (2010-2019).
- Analysis of endpoints including 30-day, 1-, 3-, and 5-year survival, freedom from cardiac allograft vasculopathy, and major adverse cardiac events.
- Statistical analysis using Cox proportional hazards modeling, propensity score matching, and Kaplan-Meier survival analysis.
Main Results:
- In unmatched cohorts, no significant survival differences were observed at any time point.
- Recipients of older donor hearts (≥55 years) showed lower freedom from cardiac allograft vasculopathy and fatal major adverse cardiac events.
- Propensity-matched analysis revealed similar survival and freedom from cardiac allograft vasculopathy, but significantly lower freedom from nonfatal major adverse cardiac events at 1, 3, and 5 years for recipients of older donors.
Conclusions:
- Carefully selected older donors can be considered for specific recipient groups.
- Outcomes are acceptable, but careful patient selection is paramount.
- Increased risk of nonfatal adverse events warrants consideration in recipients of older donor hearts.
Purpose:
Heart transplantation remains limited by donor availability. Currently, only some programs accept older donors, and their use remains contentious. We compared outcomes of heart transplant recipients who received donor hearts ≥55 years with those who received donor hearts <55 years.
Methods:
Records of first-time adult heart transplant recipients between 2010 and 2019 were reviewed. Endpoints included 30-day and 1-, 3-, and 5-year survival; freedom from cardiac allograft vasculopathy; freedom from nonfatal major adverse cardiac events; and freedom from any rejections. The effect of donor age ≥55 years was analyzed with Cox proportional hazards modeling, 1:2 propensity score matching, and Kaplan-Meier survival analysis.
Results:
Sixty-six patients received donor hearts ≥55 years and 766 received donor hearts <55 years. In the unmatched cohort, there was no significant difference in survival between the 2 groups at 30 days (93.9% vs 97.3%, P = .127), 1 year (87.9% vs 91.6%, P = .325), 3 years (86.4% vs 86.5%, P = .888), or 5 years (78.8% vs 83.8%, P = .497). The ≥55 years group had a significantly lower freedom from cardiac allograft vasculopathy and fatal major adverse cardiac events. In propensity-matched patients, recipients of donors ≥55 years had similar survival and freedom from cardiac allograft vasculopathy but significantly lower 1-year (76.7% vs 88.3%, P = .026), 3-year (68.3% vs 84.2%, P = .010), and 5-year (63.3% vs 83.3%, P = .002) freedom from nonfatal major adverse cardiac events when compared to recipients of younger donors.
Conclusions:
Carefully selected older donors can be considered for a carefully selected group of recipients with acceptable outcomes.
More Related Videos
Related Concept Videos
Kidney Transplant I: Introduction
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

